http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021155712-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d87beca8d976674bd30f2322da43a806 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0ee33b0e3e7398cf6fc957eeee59d510 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-136 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6883 |
| filingDate | 2020-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f8d3a2b8ea66f688e7eb2382a02d1e7c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c1a3b6b2108511186683cdd28e06e5fa http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_202550c1426277237f27a94e1340df82 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d162cc4c0cd1888b53d39b732cf7fb1b |
| publicationDate | 2021-08-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2021155712-A1 |
| titleOfInvention | Application of substance for detecting mecp2 mutation in detecting whether mecp2 mutation is pathogenic mutation and selecting drug |
| abstract | Provided is an application of a substance for detecting an MeCP2 mutation in detecting whether the MeCP2 mutation is a pathogenic mutation and selecting a drug. It is found that MeCP2 can be bound with nucleosome beads to generate a phase change, and both an MeCP2 pathogenic truncation mutation and a point mutation cause an abnormal phase change between MeCP2 and the nucleosome beads; an intracellular experimental result shows that only a pathogenic point mutation can cause the abnormal phase change, but a non-pathogenic point mutation has no obvious influence on the phase change, and it is further proved that the abnormal phase change is closely related to a disease caused by the MeCP2 mutation. Therefore, the reversion of the abnormal phase change is likely to become a new idea and direction for treating a related disease, a regulation substance capable of reversing the abnormal phase change can be obtained by means of high throughput screening and be applied to the development of a potential targeted drug, and the strategy can also provide reference for treating other diseases related to the abnormal phase change. |
| priorityDate | 2020-02-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 90.